ASCENTAGE PHARMA GROUP INTERNATIONAL
About ASCENTAGE PHARMA GROUP INTERNATIONAL
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $1.6B
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.6B
- Shares outstanding
- 93.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 24, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Trading 64% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ASCENTAGE PHARMA GROUP INTERNATIONAL.
Write a review
News about ASCENTAGE PHARMA GROUP INTERNATIONAL
News & sentiment via Polygon.io
